X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement option awards effective January 30, 2026, under its 2019 Inducement Equity Incentive Plan to new employees.
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement option awards effective January 30, 2026, under its 2019 Inducement Equity Incentive Plan to new employees.
The awards total 20,000 options, each with a ten‑year term and an exercise price of $3.70 (closing price on January 30, 2026). Options vest over four years (25% after 12 months, then monthly over 36 months).
In the Feb 3 session, XFOR gained 0.50%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Context
This announcement outlines a standard inducement grant of stock options for new hires, covering 20,0...
Analysis
This announcement outlines a standard inducement grant of stock options for new hires, covering 20,000 shares at an exercise price of $3.70 with a four-year vesting schedule. It follows a period characterized by sizeable financings and an active Form S-3 used via 424B5 offerings. Investors monitoring X4 may focus more on future clinical, commercial, and financing updates than on this routine compensation action when assessing the company’s trajectory.
Key Figures
Inducement options granted:20,000 sharesOption exercise price:$3.70 per shareOption term:10 years+5 more
Inducement options granted
20,000 shares
Aggregate options under 2019 Inducement Equity Incentive Plan
"These stock awards were granted as an inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement awardsfinancial
"the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan"
Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.
equity incentive planfinancial
"under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
exercise pricefinancial
"The options have a ten-year term and an exercise price of $3.70 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"Each option will vest over a four-year period, with 25% of the shares vesting after 12 months"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
award agreementfinancial
"The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement"
An award agreement is a legal contract that spells out the terms of a pay or equity grant—such as stock options, restricted shares, or cash bonuses—given to an employee, director or consultant. It describes what is being granted, any conditions for keeping it (for example, earning it over time or meeting performance targets), and what happens if the person leaves or breaks rules. Investors care because these agreements affect company costs, potential share dilution and how executives are motivated and rewarded.
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 20,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of $3.70 per share, which is equal to the closing price of X4’s common stock on January 30, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.
About X4 Pharmaceuticals X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in patients with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did X4 Pharmaceuticals (XFOR) announce on February 2, 2026 regarding inducement grants?
X4 announced the grant of options to purchase 20,000 shares to new employees under its 2019 Inducement Plan. According to the company, the awards were made effective January 30, 2026 and approved by the compensation committee in compliance with Nasdaq rules.
How many shares and what exercise price were set for the XFOR inducement options?
The company granted options covering an aggregate of 20,000 shares with an exercise price of $3.70 per share. According to the company, $3.70 equals X4's closing stock price on January 30, 2026 and is the set strike for these options.
What are the term and vesting terms for the XFOR inducement option awards?
Each option has a ten‑year term and vests over four years with standard 25% after 12 months, then monthly over 36 months. According to the company, vesting is subject to continued employment on each vesting date.
Why were inducement awards issued under Nasdaq Listing Rule 5635(c)(4) for XFOR?
The awards were issued as inducements to newly hired employees in reliance on Nasdaq Listing Rule 5635(c)(4). According to the company, the 2019 Inducement Plan is used exclusively for grants to individuals not previously employed by X4.
What shareholder impact could XFOR inducement options have if exercised?
If fully exercised, the options would result in issuance of 20,000 common shares, creating potential dilution equal to those shares. According to the company, actual shareholder impact depends on total outstanding shares and whether and when the options are exercised.
